Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pain Modulation with Nortriptyline in Refractory GERD
NCT00251732Phase 4Completed
- Sponsor
- University of Arizona
- Start
- Mar 2005
- Primary completion
- May 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of nortriptyline in gastroesophageal reflux disease (GERD) (3 arms), sponsored by University of Arizona. Primary endpoint: Symptom control after 6 weeks of treatment. Started Mar 2005; status: completed.
02
Drugs
nortriptyline
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT00251732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00251732.